key: cord-0701757-duvo9k6r authors: Lutz, Megan; Hayney, Mary S.; Farraye, Francis A.; Caldera, Freddy title: Reducing the Risk of Vaccine Preventable Diseases During the COVID-19 Pandemic date: 2020-09-24 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2020.08.011 sha: 9bdb749acda00cd6da61553fb7c2e5dbc7acd604 doc_id: 701757 cord_uid: duvo9k6r nan A dult and pediatric gastroenterologists and hepatologists often manage patients who are at increased risk for infections as a consequence of their disease or because of their use of immunosuppressive agents. Important patient groups to consider include those with inflammatory bowel disease (IBD), autoimmune hepatitis, cirrhosis, and those after a liver transplant. When including patients older than the age of 65 and the 3% of the general population who are immunosuppressed, it is clear that a substantial number of patients seen in gastroenterology and hepatology practices are at increased risk for infection. 1 Importantly, many of these infections are considered vaccine preventable diseases (VPD); however, in the months after the onset of the coronavirus disease 2019 (COVID-19) pandemic, we have seen rates of immunization, which had already been suboptimal in certain immunosuppressed populations, falling further. This has potentially grave consequences for our patients who, in addition to being at risk for COVID-19 infection, are now at risk for diseases that may have otherwise been preventable. Immunosuppressed patients in gastroenterology and hepatology practices have historically had low rates of immunization for VPDs. One frequently cited barrier to immunization is uncertainty as to which provider is responsible for recommending and providing age-appropriate vaccines. This may result in a specialist recommending immunization by the primary care provider and that recommendation failing to be implemented. 2 In addition, providers may question the safety and effectiveness of vaccination in an immunosuppressed group. Fortunately, increasing research in this area has offered guidance for special populations, including those on immunosuppressive medications for IBD as well as after solid organ transplant (Table 1 ). 2, 3 In addition to these common barriers, providers face a new set of challenges because of rapid clinical procedural changes taking place in the setting of COVID-19. Significantly fewer in-person visits are occurring in specialty as well as primary care practices, decreasing the chances for patients to receive their immunizations at office appointments and leading to a significant decrease in the number of vaccines administered. During an approximately 3-month period in 2020 compared with 2019, there have already been more than 400,000 fewer doses of measles-containing vaccines ordered through the Vaccines for Children Program, a federally funded program that provides about 50% of US vaccines to children. 4 Similarly, data from a pediatric population in Michigan now indicate that less than half of children age 2 years and younger are up to date on immunizations. 5 Data in the adult population are only beginning to emerge. In the state of Wisconsin, number of vaccines administered in the year 2020, which before the pandemic had outpaced the average number of vaccines administered during the past 5 years, fell to fewer than half of the number that had been seen previously as COVID-19 cases increased and policies were put in place to reduce the spread of the virus. In those patients aged 19 years and older, number of vaccines administered as compared with previous years declined even more sharply (Figure 1 ). Decrease in the number of vaccines administered may result in loss of herd immunity for certain VPD, such as measles, polio, and diphtheria, and increase the risk of a VPD outbreak, a potentially dangerous scenario for immunosuppressed populations in the setting of an already strained healthcare system. 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 Several variables must be taken into account when determining the balance of risk and benefit in administering routine immunizations in the midst of a pandemic. According to the World Health Organization, these variables should include the epidemiology of the VPD, the epidemiology of COVID-19 in that region, the ability of the healthcare system to deliver vaccines, and the supply of the vaccine. 6 Because both COVID-19 and VPD such as influenza or invasive pneumococcal disease are threats to our immunosuppressed patients, we must take advantage of alternate opportunities to deliver vaccinations in ways that do not increase patients' exposure to the disease. We propose several possible strategies for specialists to lead this effort and are currently working to improve and implement these measures at our own institutions. First, we believe it is necessary to use the opportunity of any in-person office visit to administer immunizations rather than recommending they be administered by another provider. The Community Preventive Services Task Force, a group of population health experts established by the US Department of Health and Human Services, offers several evidence-based directives to improve immunization rates that are practical in a specialty clinic and have durable results. These include client recall systems, provider reminders, standing orders (ie, a protocol put in place to allow non-physician providers to prescribe and administer appropriate vaccines without a physician order), and immunization information systems such as access to state immunization registries ( Table 2) . 7 Ideally these strategies are used in tandem and embedded in the healthcare system; however, even simple measures such as receiving personal feedback on immunization rates can serve to increase these rates. Similarly, previous work has shown that easily implemented specialty care clinic systematic approaches (ie, patient completion of a questionnaire regarding immunization history that is then verified by a provider so office staff can administer vaccines) can greatly improve vaccination rates. 8 Now is the time to improve immunization rates in our specialty practices; however, we recognize that many patients are not being seen in specialty offices and instead primarily seen via telehealth. For those patients, efforts should be made to add vaccine appointments to other in-person healthcare appointments, including blood draws, endoscopic procedures, imaging studies, nurse appointments, or any other in-person ancillary appointment. Visiting nurses who may already see patients for medication management or infusions of biologics or total parenteral nutrition, for example, may also administer immunizations. At our own institutions, we are planning to administer Improving vaccination rates in our immunosuppressed population should be an effort led by gastroenterologists and hepatologists. As we lose opportunities to immunize patients in the office, we must rely on these strategies listed above to ensure that herd immunity is not lost to certain VDP and to prevent the potentially dangerous scenario of multiple simultaneous epidemics. Combinations of interventions, particularly those that are embedded in the healthcare system, are effective and have durability. The improvements we make to increase accessibility to vaccines will continue to be important after the pandemic because many changes resulting from COVID-19, such as fewer in-person visits and more telehealth, will likely persist in some capacity indefinitely. Preventive health remains of high importance even in a pandemic, and eventually these strategies we develop now can be used to effectively administer COVID-19 vaccines in the future. 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 Prevalence of immunosuppression among US adults Optimizing immunization strategies in patients with IBD Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration: United States Decline in child vaccination coverage during the COVID-19 pandemic: Michigan Care Improvement Registry Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region Increasing coverage of appropriate vaccinations: a community guide systematic economic review A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD The authors thank the Wisconsin Division of Public Health, Immunization Program for providing Figure 1 . These authors disclose the following: Dr Freddy Caldera has received research support from Takeda Pharmaceuticals and Sanofi and has been a consultant for Takeda, Arena Pharmaceuticals, GSK, and Celgene. Dr Farraye is a consultant for BMS, Braintree Labs, Gilead, GSK, Innovation Pharmaceuticals, Janssen, Pfizer, and Sebela and sits on a DSMB for Lilly and Theravance. Dr Hayney is a consultant for GSK Vaccines and Seqirus and has received research support from Takeda Pharmaceuticals and Sanofi. The remaining author discloses no conflicts.-2020 ---